Kornimate/medical-research-clean huggingface dataset:
effects of whole body vibration in different devices on bone and muscle mass in postmenopausal women

Conditions: Bone Density; Muscles; Physical Functional Performance; Accidental Falls; Quality of Life

Summary: postmenopausal women suffer from a series of negative health factors, such as decreased bone and muscle mass and physical performance, increasing the risk of falls and decreasing quality of life. therefore, intervention strategies aimed at mitigating these factors are essential. a technique that has been studied and can reverse these factors is whole-body vibration (wbv), however studies present contradictory results and the main confounding factor appears to be related to the type of vibration (synchronous or side-alternating). therefore, the primary objective of this project is to verify the effects of 12 months of whole-body vibration on different devices on bone mineral density measurements in postmenopausal women. as a secondary objective, the effects on muscle mass, physical performance, quality of life and falls will be verified. 228 postmenopausal women will participate in the study and will be randomized to: triplanar vibration (synchronous); side-alternating vibration; or false vibration. the interventions will last 12 months and will occur three times a week on non-consecutive days. the following assessments will be carried out at baseline, 6-months and 12-months: bone mineral density and muscle mass by dxa equipment, muscle thickness by ultrasound, peak torque of the knee extensor and flexor muscles by an isokinetic dynamometer, hand grip, balance static postural and vertical jump on a force platform, dynamic balance using the timed up and go test, sppb battery, fear (fes-i) and incidence of falls and quality of life (sf-36).


Eligibility criteria:
inclusion criteria: * being postmenopausal (without menstruating for at least 12 months); * not performing physical exercise systematically for at least 6 months; * not needing assistance to carry out daily tasks; * do not present serious cognitive problems that make it impossible to understand simple commands; * do not have serious dysfunctions or implants in the spine, hips or lower limbs; * not have neurological diseases or diseases that affect bone metabolism; * do not have vascular diseases, arrhythmia, use a pacemaker, suffer from epilepsy or seizures; * no diseases/problems that affect the retina; * do not present severe labyrinthitis or vertigo; * not using medication/supplements to increase bone and/or muscle mass for at least 6 months; * have not undergone cancer treatment in the last 5 years. exclusion criteria: * withdraw from participating in the study for any reason; * present adverse events during interventions that cannot be controlled.
quantitative us for hepatic steatosis

Conditions: Hepatic Steatosis

Summary: the purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction (mri-pdff) and mr spectroscopy as the reference standard.


Eligibility criteria:
inclusion criteria: * patients with clinically suspected non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash), or living-donor candidates for liver transplantation, or volunteers * signed informed consent exclusion criteria: * chronic liver disease patients (serum hbsag positive or anti-hepatitis c virus (hcv), histologic confirmation) * chronic alcoholics * serum alanine transaminase (alt)\>5 times the upper limit of normal within 3 months * previous liver surgery * acute hepatitis or bile duct obstruction
surveying knowledge, attitudes, and practices of primary care physicians in turkey regarding osteoporosis management.

Conditions: Osteoporosis

Summary: this study aims to assess the knowledge of primary care physicians on the diagnosis and treatment of osteoporosis.

multiple choice questions will be used to assess information related to the diagnosis and treatment of osteoporosis, including knowledge of various medications, their mechanisms of action and side effects, and recommended dosage of vitamin d supplementation. the participating physicians will also be asked about their sources of knowledge acquisition and how they keep updated on this topic, as well as their self-evaluation of knowledge. furthermore, background information will be collected, including professional and demographic characteristics. a questionnaire previously used in other studies will be adapted for the study based on the 'updated approach for the management of osteoporosis in turkey: a consensus report'.

Eligibility criteria:
inclusion criteria: * giving consent. * working as a family physician assistant, family physician specialist or general practitioner in turkey. exclusion criteria: * not giving consent. * having any physical or mental illness that may prevent reading, understanding and filling out the form.
transplantation for easl-clif and apasl aclf patients: a retrospective cohort study

Conditions: Acute-On-Chronic Liver Failure; Liver Cirrhosis; Liver Transplant; Complications

Summary: the definition and diagnostic criteria of acute-on chronic liver failure (aclf) differed evidently between the east and the west due to the difference in the underlying etiology. liver transplantation is the most effective treatment to reverse the progress of aclf and improve the survival rate of patients. the purpose of this study is to explore the accuracy of the two diagnostic criteria of easl-clif and apasl aclf in assessing the survival rate of patients with liver cirrhosis after lt.

a retrospective collection and analysis of the preoperative conditions of patients with lt due to cirrhosis in a single center from january 2015 to june 2020 would be conducted, including epidemiological characteristics, etiology, clinical indicators, and short-term (28 days, 90 days) and long-term (1 year, 3 years) survival after lt.

Eligibility criteria:
inclusion criteria: * patients underwent liver transplantation for cirrhosis * the diagnosis of aclf followed apasl and easl-clif definition. exclusion criteria: * patients with malignant tumor or underwent living donor liver transplantation (ldlt) were excluded.

Keywords: acute-on-chronic liver failure easl-clif criteria apasl criteria
train the brain with music: brain plasticity and cognitive benefits induced by musical practice in elderly people

Conditions: Age-related Cognitive Decline

Summary: this longitudinal study aims to countervail age-related cognitive and cerebral decline in healthy retired people through intensive piano / keyboard music practice in switzerland and germany.

recent data suggest that music making might prevent cognitive decline in the elderly. however, experimental evidence remains sparse and no information on the neurophysiological basis has been provided, although cognitive decline is a major impediment to healthy aging. this study combines for the first time protocolled music practice in elderly with cutting-edge neuroimaging. the investigators propose a multi-site hannover-geneva longitudinal randomized intervention study in altogether 100 retired healthy elderly (64-76) years, 70 geneva, 100 hannover), offering either piano instruction or instruction on musical culture for one year. participants will be tested at 3 time points on cognitive, perceptual and motor abilities as well as via wide-ranging functional and structural neuroimaging data (magnetic resonance imaging, mri). the research team expects positive transfer effects from intensive piano training not only on subjective well-being, but also on executive functions, working memory, hearing in noise and relationships of these behavioral features with morphological and functional brain plasticity. this study may therefore for the first time be demonstrate, that music making can provoke important societal impacts by diminishing cognitive and perceptual-motor decline underpinned by functional and structural brain plasticity.

Eligibility criteria:
inclusion criteria: * healthy right-handed volunteers, between 64 and 76 years of age, native french speakers. no regular musical practice over the lifespan. only retired individuals may participate. exclusion criteria: * impaired/not-corrected auditory or visual accuracy, neurological diseases in the present or the past, cardiovascular diseases, excessive hypertension, obesity, diabetes mellitus, beginning dementia, mild cognitive impairment, clinical depression.

Keywords: countervail age-related cognitive and cerebral decline healthy elderly musical training neuroimagery and brain plasticity psychometrics executive function mental health well-being sensorimotor function
impairments of oral language in mobius syndrome

Conditions: Möbius Sequence

Summary: the möbius syndrome constitutes a congenital disorder classically caused by genetic and environmental factors. the clinical manifestations include lesion of the facial and abducens nerves associated with limb malformations specially club foot. the speech-language manifestations include compromise of oral and deglutition, speech and language functions, secondary to cranial nerves lesions and mental retardation. the language compromise in this disorder is still not well known. in this way, the main objective of this study is to characterize the oral language in a population of fifteen subjects with möbius syndrome with age ranging from two to thirteen years old, from both sexes, seen in one of the three main center for genetic diagnosis in the state of ceará. the present work is a descriptive study of a cross-sectional design conducted from february to december/2002, using a clinical evaluation of language components including morphology, syntax, semantics and pragmatics. the investigators identified exclusive speech involvement in 20,0% of the subjects, language disturbance in 46,7%, speech and language disturbance in 13,3% and oral language involvement in 26,7%. the investigators conclude that the language disturbance in the möbius syndrome presents with a variable compromise of all oral language components. the delay in linguistical development, incomprehensive speech and the deficit of constructions of sentences and narrations are constant.

in this way, the main objective of this study is to characterize the oral language in a population of fifteen subjects with möbius syndrome with age ranging from two to thirteen years old, from both sexes, seen in one of the three main center for genetic diagnosis in the state of ceará. the present work is a descriptive study of a cross-sectional design conducted from february to december/2002, using a clinical evaluation of language components including morphology, syntax, semantics and pragmatics.

Eligibility criteria:
inclusion criteria: * möbius syndrome * age ranging from two to thirteen years old. exclusion criteria: * others diseases with impact in oral language.

Keywords: möbius syndrome language speech, language and hearing sciences
video and brochure and discharge instructions for childhood fever in the pediatric emergency department

Conditions: Fever; Child, Only

Summary: this study was designed to evaluate whether adding video discharge instructions to usual verbal information improves understanding of the information provided to caregivers of patients presenting to pediatric emergency departments for high fever. as secondary goals, it was aimed to assess whether video discharge instructions increase satisfaction with information received and reduce repeat visits.

the research will be carried out in a randomized controlled manner. there will be three groups in the research: those who received video (intervention), brochure (intervention) and verbal (control) discharge instructions. a power analysis was performed based on the number of children in both groups, in another study in which the scales to be used in the research were used. according to the calculations made in the g-power 3.1 demo package program, when the effect size was accepted as 0.8, it was seen that at least 48 cases in each group would be sufficient for 80% power. children who meet the research criteria will be assigned a random number to the intervention and control groups via http://www.randomize.org/ by numbering the order of arrival at the hospital. research data will be collected using descriptive information form and parental fever management scale and post-discharge data collection form.

Eligibility criteria:
inclusion criteria: * the child is between 1 month and 18 years old * parent's consent to participate in the research * parent's completion of all pre-and post-education follow-up exclusion criteria: * the child is not between 1 month and 18 years old * the child does not undergo day surgery. * parent's refusal to participate in the research * parent not completing all pre- and post-education follow-up
targeted cpap therapy for obstructive sleep apnea in pregnancy

Conditions: Obstructive Sleep Apnea

Summary: prospective, randomized controlled trial. pregnant women in early pregnancy will be randomized to either the sleep study + cpap (continuous positive airway pressure therapy) group or to a standard prenatal care group. subjects in the sleep study + cpap group will complete a sleep study (watchpat-200, itamar medical, inc.) and have cpap initiated if the apnea hypopnea index (ahi) ≥5 as indicated, in early and late pregnancy, whereas the other group will receive standard prenatal care. all subjects will complete a sleep study again between 8 to 12 weeks postpartum.

objective/hypothesis: the purpose of this study is to determine if parturients identified as high risk for obstructive sleep apnea (osa; defined as an apnea hypopnea index \[ahi\] ≥5 events/hour) who are randomized to receive an unattended sleep study during early and late pregnancy (early = between 6 and 16 weeks; late = between 27 and 33 weeks) plus initiation of cpap therapy if the ahi ≥5 events/hour and standard prenatal care have a decreased incidence of adverse pregnancy outcomes (defined as a composite variable which includes gestational hypertension, preeclampsia, eclampsia, gestational diabetes, preterm birth, low birth weight, or stillbirth) at the time of delivery when compared to a group who receives standard prenatal care only (no sleep study and cpap initiation). at 8 to 12 months postpartum subjects in both groups will complete a sleep study.

Eligibility criteria:
inclusion criteria 1. at least one of the following risk factors for osa: prepregnancy bmi ≥ 30kg/m2, chronic hypertension, pregestational diabetes, twin gestation, or a history of prior pregnancy affected by: preeclampsia, eclampsia or fetal growth restriction. 2. between 6 and 16 weeks gestation at time of enrollment. exclusion criteria 1. current diagnosis and treatment of osa. 2. patient refusal to randomization. 3. permanent pacemaker (interfere with watchpat sleep study). 4. currently taking alpha blockers or nitrates (interfere with watchpat sleep study). 5. coronary artery disease or congestive heart failure or cardiomyopathy. 6. not delivering and completing their postpartum visit at naval medical center san diego (nmcsd). 7. inability to read or understand the consent. 8. \<18 years of age.

Keywords: osa pregnancy adverse pregnancy outcomes continuous positive airway pressure preeclampsia gestational diabetes
single-center investigator initiated pilot study investigating the tumor response of squamous cell carcinoma lesions in patients under lapatinib treatment

Conditions: Squamous Cell Carcinoma

Summary: primary cutaneous squamous cell carcinomas (sccs) are epithelial carcinomas with a high frequency of egf-r expression. egfr is an important regulator of tumour progression and proliferation in several types of cancer. mechanism of action of lapatinib in the egfr and/or her2 expressing oesophageal squamous cell carcinoma (escc) cells is attributed to inhibition of cell proliferation and induction of apoptosis. based on the data from oesophageal sccs the investigators hypothesise that egfr signalling pathway and its interactions play an important role in the scc pathogenesis and represent a good therapeutic target from these tumours. primary objectives: to evaluate the tumour response macroscopically in patients with primary cutaneous scc lesions and in concomitant scc in situ (ak). secondary objectives: * to evaluate tolerability of a single dose regimen of systemic lapatinib therapy in patients with scc as measured by time to first ae or sae within the study period. * to investigate the molecular tumour response of squamous cell carcinoma lesions in patients under lapatinib treatment using a set of variables. * trial with medicinal product


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of histologically confirmed cutaneous scc stage tis-t2n0 for which surgical treatment is considered suitable. * in case of scc, patients must present with a minimum of two co-existing ak lesions. in case of keratoacanthoma, one lesion of sufficient size (=1cm) is acceptable. * all included patients must have both ffpe and frozen material available. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * adequate organ system function exclusion criteria: * subjects who have current active hepatic or biliary disease * other non-controlled malignancy * clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding. * history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of study treatment. * presence of uncontrolled infection * history of any one or more of the following cardiovascular conditions within the past 6 months:cardiac angioplasty or stenting;myocardial infarction;unstable angina;coronary artery bypass graft surgery;symptomatic peripheral vascular disease; class iii or iv congestive heart failure, as defined by the new york heart association (nyha) * poorly controlled hypertension * history of cerebrovascular accident including transient ischemic attack (tia), pulmonary embolism or untreated deep venous thrombosis (dvt) within the past 6 months. * prior exposure to the study drug lapatinib * prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer
comparison of breathing event detection by a continuous positive airway pressure device to clinical polysomnography

Conditions: Sleep Apnea Central; Cheyne-Stokes Respiration; Obstructive Sleep Apnea

Summary: the purpose of this study is to demonstrate diagnostic agreement and determine the accuracy of the continuous positive airway pressure (cpap) device compared to simultaneous, attended clinical polysomnography (psg) in identifying breathing events in participants previously diagnosed with complex sleep apnea (compsas), complex sleep apnea with cheyne-stokes respiration (csr), or obstructive sleep apnea (osa).

study objectives: to compare a positive airway pressure (pap) device's detection of respiratory events and airway status during device detected apneas with events scored on simultaneous polysomnography (psg). design: prospective psgs of patients with sleep apnea using a new-generation pap device. settings: four clinical and academic sleep centers. patients: forty-five patients with obstructive sleep apnea (osa) and complex sleep apnea (comp sa) performed a psg on pap levels adjusted to induce respiratory events. interventions: none.

Eligibility criteria:
inclusion criteria: * males and females, ages 21-80. * able and willing to provide written informed consent. * diagnosis of complex sleep apnea (compsas) or obstructive sleep apnea (osa) within one year of study participation. * for participants with compsas: (a) diagnostic psg with an apnea-hyopnea index (ahi) greater than or equal to 10 events/hour and central apnea index (cai) greater than or equal to 5 events/hour of sleep or (b) pap titration with a cai greater than or equal to 5 events/hour of sleep. * for participants with osa, a diagnostic psg with an ahi greater than or equal to 15 events/hour of sleep. * must have had a cpap titration such that the necessary pap level to treat the sleep disordered breathing is known. * agreement to undergo a full-night, in-laboratory psg on cpap device. exclusion criteria: * participation in an interventional research study within 30 days of study participation. * pre-menopausal females known to be pregnant or who are sexually active and not using a reliable method of birth control. * surgery of the upper airway, nose, sinus, or middle ear within the last 90 days. * surgery at any time for the treatment of osa such as uvulopalatopharyngoplasty (uppp). * major medical or psychiatric condition that would interfere with the demands of the study, adherence to positive airway pressure, or the ability to complete the study. * chronic respiratory failure or insufficiency with suspected or known neuromuscular disease, moderate or severe chronic obstructive pulmonary disease (copd) or other pulmonary disorders, or any condition with an elevation of arterial carbon dioxide levels (\> 45 mmhg) while awake. * currently prescribed oxygen therapy. * ventilatory induced barotrauma within 6 months of study participation. * untreated insomnia. * other major medical condition that, in the judgment of the investigator, precludes participation in this study.
study to evaluate the benefit of ruconest in improving neurological symptoms in post covid-19 infection

Conditions: Post-Viral Fatigue Syndrome; Post-Viral Disorder (Disorder); Covid19

Summary: randomized, double blind, placebo controlled, proof-of-concept study to evaluate the benefit of ruconest in improving neurological symptoms in post-sars-cov-2 infection.

this study will last approximately 19 weeks including 16 infusions total, each one week apart. this is to help patients that have developed "post-viral fatigue syndrome" which can include symptoms such as: extreme fatigue, lost of taste, brain fog, and/or seizures.

Eligibility criteria:
inclusion criteria: 1. age 18 and older, male or female 2. previous confirmed diagnosis of sars-cov-2 3. experiencing sars-cov-2 post-viral fatigue syndrome 4 weeks after recovery for sars-cov-2 4. experiencing neurological symptoms including fatigue 5. willing to comply with all aspects of the protocol, including blood draws 6. patient is able to understand and fully participate in the activities of the study and the consent in accordance with guidelines 7. female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception. acceptable forms of contraception are defined as those with a failure rate of \< 1% when properly applied and include: a combination pill, some intra-uterine devices, and a sterilized partner in a stable relationship. female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire period. exclusion criteria: 1. receiving any form of c1-inh therapy either acute or prophylactic treatment 2. history or suspicion of allergy to rabbits 3. neurological conditions related to injury 4. neuropathy related to diabetes 5. participants who are pregnant or lactating 6. largely incapacitated or bed ridden 7. currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued with 30 days of study entry from any other clinical study involving an investigational product 8. patients who, in the investigator's opinion, might not be suitable for the trial for safety reasons

Keywords: post-covid symptoms post-viral fatigue syndrome